-
6 days ago | 
fiercepharma.com | Zoey Becker
AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle-invasive bladder cancer (NMIBC).
-
6 days ago | 
fiercebiotech.com | Darren Incorvaia |Zoey Becker
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Zoey Becker and it will be featured here at the end of each week.
-
1 week ago | 
fiercepharma.com | Zoey Becker
This time last year, Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 billion Japanese yen ($899 million) restructuring campaign. Now, things are looking up for the Japanese drugmaker with several key products keeping it afloat as it looks to unlock a new path to growth with upcoming launches.
-
1 week ago | 
fiercebiotech.com | Zoey Becker
Beacon Therapeutics may have found a guiding light in a disease area where other companies have stumbled with its laruparetigene zovaparvovec (laru-zova), a gene therapy that proved early improvements in patients with X-linked retinitis pigmentosa (XLRP).
-
1 week ago | 
fiercepharma.com | Zoey Becker
For Vertex, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment Journavx contributed to a U.S. revenue boost and the company's increased 2025 outlook. But on the other hand, a unique generics situation in Russia weighed on the biopharma's international sales.
-
1 week ago | 
fiercepharma.com | Zoey Becker
Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the companies laid the case to rest with a settlement agreement. Novartis and Incyte jointly agreed to ask that District Judge Gregory H. Woods adjourn the planned trial in favor of a final settlement agreement, court filings show. With that, both sides have laid down their swords in the case, which is linked to a 2009 agreement between the two companies.
-
1 week ago | 
fiercebiotech.com | Zoey Becker
Unity Biotechnology and Mammoth Biosciences are bpth turning toward cost-saving measures, prompting layoffs at both companies. Unity’s restructuring comes along with 36-week results from its phase 2b Aspire trial that weighed its investigational eye treatment UBX1325 against Regeneron’s blockbuster Eylea in patients with diabetic macular edema who had poor vision despite prior treatment.
-
1 week ago | 
fiercepharma.com | Zoey Becker
As sure as the sun rises, prescription medicine use and total drug spending continues to increase in the U.S.To better understand how these trends will play out in the near-term, the life sciences intelligence firm IQVIA Institute recently dropped a deep dive on medicine usage patterns backed by findings from 2024.
-
1 week ago | 
fiercepharma.com | Zoey Becker
Sanofi is racing to raise the flag on meningitis awareness—literally. The Paris-based pharma is fittingly symbolizing the “race against time” that is the fight against rapidly progressing bacterial meningitis with its Meningitis Flag, which United Autosports’ #59 McLaren will bear while racing in this year’s 24 Hours of Le Mans car race in France in June. Meningitis is contracted by someone in the world every 15 seconds, Sanofi explained in a press release.
-
1 week ago | 
fiercebiotech.com | Darren Incorvaia |Zoey Becker |Gabrielle Masson
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Zoey Becker and it will be featured here at the end of each week. Scholar Rock rocks the boat with new execsScholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal muscular atrophy drug apitegromab later this year.
